A
Akebia Therapeutics
Development and commercialization of therapeutics for patients with chronic kidney disease
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with chronic kidney disease (CKD). The company primarily focuses on addressing anemia associated with CKD through its lead product candidate, vadadustat, which is currently undergoing global Phase 3 clinical trials. Akebia serves patients, families, and medical professionals by providing cutting-edge treatments aimed at improving the quality of life for those affected by kidney disease. Operating in the biopharmaceutical market, Akebia's business model involves extensive research and development, clinical trials, and strategic partnerships to bring its therapies to market. Revenue is generated through product sales, licensing agreements, and collaborations with other healthcare organizations. The company is headquartered in Cambridge, MA, and actively participates in major healthcare conferences to present its findings and advancements.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2014
- Outcome tier
- Thoroughbred$100M+ revenue
News
Open roles
Akebia Therapeutics in the Cambridge ecosystem
The Akebia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CincyTech
Series A8 investors entered at this stage
Venture Investors Health Fund
Novartis Venture Fund
Athenian Venture Partners- KPKearny Venture Partners
Orchard Venture Partners- TPTriathlon Medical Venture Partners
QCA Ventures
GeneChem
Series B and later3 investors entered at this stage
Novo Seeds
Novo Holdings
Kreos Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
50 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Akebia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Akebia Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


